Noncash interest expense on deferred royalty obligations

Name: BridgeBio Pharma Noncash interest expense on deferred royalty obligations by Business Segments
Creator: OpenCapital
License: https://www.opencapital.sh/terms

BridgeBio Pharma·Business Segments·1 segment·Rolls up to Noncash interest expense on deferred royalty obligations

Breakdown

Segment	Q3 '25	Q4 '25	Q1 '26
Business Segments	$36.41M	$38.68M	$39.87M
Total	$36.41M	$38.68M	$39.87M

Segments

Business SegmentsView metric